BA3 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Liquidity & Low LeverageA large cash balance and effectively zero debt provide durable financial flexibility to fund product development, complete remediation work, pursue complementary M&A (e.g., UK Biocentre), and absorb cyclical softness without near-term refinancing risk, supporting multi‑quarter execution.
Durable Recurring Revenue BaseHigh‑growth biorepository and outsourced sample management generate predictable, service‑driven revenue and consumables pull‑through. This recurring mix cushions capital equipment cyclicality, supports steadier gross margins, and underpins durable top‑line resilience over several quarters.
Operational Execution Improvements (ABS)Meaningful gains in delivery performance and RNA‑Seq speed reflect lasting process and product improvements via the Azenta Business System. Better service levels improve customer retention, shorten sales cycles, enhance competitive differentiation, and support margin recovery as volumes normalize.
Bears Say
Persistent Negative ProfitabilityDespite revenue growth, consistent net losses and negative ROE indicate the business still struggles to convert sales into sustainable profits. That limits reinvestment capacity, keeps reliance on cash reserves for strategic initiatives, and makes durable margin improvement a key execution risk.
Large Goodwill ImpairmentsSubstantial impairment charges signal that past acquisitions failed to meet expectations, eroding equity and reflecting weaker forward cash‑flow assumptions. These write‑downs reduce strategic optionality, raise scrutiny on acquisition discipline, and can weigh on long‑term investor confidence.
Automated Storage Quality Issues & Order PushoutsQuality remediation and delayed large cryo/automated‑store deals reduce revenue visibility and defer high‑margin instrument sales. Ongoing remediation costs and weaker conversion of the pipeline can compress margins and slow durable growth in capital‑equipment segments for multiple quarters.
Azenta News
BA3 FAQ
What was Azenta’s price range in the past 12 months?
Currently, no data Available
What is Azenta’s market cap?
Azenta’s market cap is CHF1.05B.
When is Azenta’s upcoming earnings report date?
Azenta’s upcoming earnings report date is Aug 04, 2026 which is in 2 days.
How were Azenta’s earnings last quarter?
Azenta released its earnings results on May 05, 2026. The company reported -CHF0.032 earnings per share for the quarter, missing the consensus estimate of CHF0.099 by -CHF0.132.
Is Azenta overvalued?
According to Wall Street analysts Azenta’s price is currently Undervalued.
Does Azenta pay dividends?
Azenta does not currently pay dividends.
What is Azenta’s EPS estimate?
Azenta’s EPS estimate is 0.09.
How many shares outstanding does Azenta have?
Currently, no data Available
What happened to Azenta’s price movement after its last earnings report?
Azenta reported an EPS of -CHF0.032 in its last earnings report, missing expectations of CHF0.099. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Azenta?
Currently, no hedge funds are holding shares in CH:BA3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF21.40 (― Upside)
CHF21.40 (― Upside)
Blogger Sentiment
Bullish
CH:BA3 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $163.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Company Description
Azenta
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
BA3 Company Deck
BA3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call was mixed. Positive operational and recurring-revenue trends (strong biorepository growth, improved on-time delivery, faster RNA-Seq turnaround, solid cash position, and targeted cost savings) coexist with significant near-term challenges: organic revenue decline, notable margin compression, large goodwill impairments (~$149M), automated storage quality remediation and delayed large-capex orders, and a guidance reset lowering FY26 growth and profitability expectations. Management reiterated long-term conviction in strategic priorities and outlined actions (leadership changes, ABS deployment, cost reductions, M&A integration) to address execution gaps, but near-term results and uncertainty weighed on the quarter.View all CH:BA3 earnings summaries